Purchase this article with an account.
David Dyer, William Anderson, Michael Patrick Ellis, Robert Breeden; Extended Follow-up of Ocriplasmin for Vitreomacular Traction Release. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1204.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the parameters that may be predictive in which ocriplasmin (Jetrea®) may be more likely to lyse vitreomacular adhesions in patients with vitreomacular traction (VMT). The main parameter analyzed was size of greatest linear dimension (GLD) and resolution was followed out to 12 months follow-up.
A retrospective chart review of consecutive VMT cases treated with ocriplasmin intravitreal injection and followed for at least 1 month and no greater than 12 months. Status of VMT resolution was assessed using Spectral Domain Optical Coherence Tomography (SD-OCT). Several parameters were assessed including coexisting ocular conditions to create a more thorough sub-analysis of the use of ocriplasmin. Information was recorded at intervals of date pre-injection, date of injection, 1 month, 3 months, 6 months and 12 months post-injection.
36 eyes were followed retrospectively for an average of 6.7 ± 4.3 months in 34 patients, 19 (55.9%) male and 15 (44.1%) female. Complete resolution of VMT status post ocriplasmin injection was seen in 13 of 36 eyes (36.1%) at a mean of 39.5 days follow-up. 3 of the 13 eyes (23.1%) that had resolving VMT, resolved after the 1 month follow-up point. The mean GLD of VMT resolution was 367 ± 97 microns.
Ocriplasmin intravitreal injection is an effective alternative to vitrectomy in many patients with VMT. Our results show a private-practice example that the drug may be used most effectively in the patients with a GLD of <550 microns.
This PDF is available to Subscribers Only